Latest Content

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.

Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.

The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.

The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.

The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.

Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.

During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.

The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.

More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.

At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.

During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.

The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.

Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.

Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.

Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.

UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.

In patients 45+ with papillary thyroid cancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification.

Selpercatinib achieved a 53% objective response rate in pediatric patients with RET-altered solid tumors, with no treatment discontinuations due to treatment-related adverse events in LIBRETTO-121.

Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.

Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.

J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.

The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.

Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.

The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.

Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.

During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.

The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.